Your session is about to expire
← Back to Search
Device
Brain Stimulation for Working Memory
N/A
Recruiting
Led By Hamdi Eryilmaz, Ph.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 hours
Summary
This trial will use a non-invasive electrical stimulation to modify brain activity and measure its effect on working memory.
Who is the study for?
This trial is for individuals who can give informed consent and are fluent in English. It's designed to explore how working memory functions by using a noninvasive brain stimulation technique.
What is being tested?
The study tests two types of transcranial alternating current stimulation (tACS): 'Active tACS' which actually modulates brain activity, and 'Placebo tACS', which does not have an active effect. The impact on working memory will be measured with EEG.
What are the potential side effects?
tACS may cause mild side effects such as tingling, itching or discomfort at the electrode sites on the scalp during application. More serious side effects are rare.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Fronto-parietal theta phase synchronization
Theta-gamma cross-frequency coupling
Working memory accuracy
+1 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Theta-nested gamma tACS applied during passive task epochsExperimental Treatment1 Intervention
Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during fixation periods between consecutive task trials. EEG will be acquired before and immediately after the intervention.
Group II: Theta-nested gamma tACS applied during memory delaysExperimental Treatment1 Intervention
Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. EEG will be acquired before and immediately after the intervention.
Group III: Gamma tACS applied during memory delaysExperimental Treatment1 Intervention
Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. The stimulation will be phase locked to the peaks of ongoing theta rhythms of the participant. EEG will be acquired before and immediately after the intervention.
Group IV: Placebo tACS applied during task performancePlacebo Group1 Intervention
Participants will receive single-session administration of placebo tACS during performance of a working memory task. EEG will be acquired before and immediately after the intervention.
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,026 Previous Clinical Trials
13,413,757 Total Patients Enrolled
Hamdi Eryilmaz, Ph.D.Principal InvestigatorMassachusetts General Hospital
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am currently taking medication for my mental health.I am not currently using drugs that affect brain stimulation therapy.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo tACS applied during task performance
- Group 2: Theta-nested gamma tACS applied during passive task epochs
- Group 3: Theta-nested gamma tACS applied during memory delays
- Group 4: Gamma tACS applied during memory delays
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.